

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/014706-2026>

Planning

NHS Branded Medicines - Tranche B - 1 September 2026

NHS England

UK2: Preliminary market engagement notice - Procurement Act 2023 - [view information about notice types](#)

Notice identifier: 2026/S 000-014706

Procurement identifier (OCID): ocds-h6vhtk-051a9d

Published 18 February 2026, 12:08pm

Changes to notice

This notice has been edited. The [previous version](#) is still available.

Registration starts date updated

Scope

Reference

CM_PHR_25_5731

Description

NHS Branded Medicines Tranche B - Lot 1 - London & South of England -
CM/PHR/25/5731

Period of Framework Agreement: 1 September 2026 to 31 August 2028 with an option or option(s) to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Commercial tool

Establishes a framework

Total value (estimated)

- £592,363,416 excluding VAT
- £710,836,100 including VAT

Above the relevant threshold

Contract dates (estimated)

- 1 September 2026 to 31 August 2028
- Possible extension to 31 August 2030
- 4 years

Main procurement category

Goods

CPV classifications

- 33600000 - Pharmaceutical products

Contract locations

- UKJ - South East (England)
- UKK - South West (England)
- UKI - London
- UKF - East Midlands (England)
- UKG - West Midlands (England)
- UKC - North East (England)
- UKD - North West (England)

Engagement

Engagement deadline

27 January 2026

Engagement process description

NHS England advises suppliers of an upcoming tender for the NHS Branded Medicines Agreement – Tranche B - Lot 1, scheduled to commence on 1 September 2026 for a

24-month term, with an option to extend for a further 24 months.

Lot 2 - Ustekinumab for North of England and Midlands & East, period of Framework Agreement: 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

The purpose of this notice is to inform existing and potential suppliers that, where deemed beneficial, a virtual 1:1 preliminary market meeting can be arranged. Please contact Trushal.Patel@nhs.net to register your interest. A seven-day window for queries will be available via Atamis after all sessions have concluded.

This framework will cover six therapy areas including adalimumab, bevacizumab, cytokine modulators, interleukin inhibitors, JAK inhibitors, and monoclonal antibodies.

Participation

Particular suitability

Small and medium-sized enterprises (SME)

Submission

Publication date of tender notice (estimated)

23 February 2026

Contracting authority

NHS England

- Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

Contact name: Lynne Tierney

Email: lynne.tierney@nhs.net

Website: <https://www.england.nhs.uk/>

Region: UKI45 - Lambeth

Organisation type: Public authority - central government